Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Our volunteers generously give us their time, skills and experience to tell people about our work, and to help us raise vital funds for research into better treatments and ultimately a cure for T1D.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & Events > Sign up for our newsletter
Subscribe to receive Breakthrough T1D’s e-newsletters and you’ll be the first to know about all of this and more.
We promise to keep your details secure and we won’t share your information with any other organisations. If you decide you’d rather not hear from us then you can unsubscribe at any time.
To sign up, simply complete your details below and click subscribe.
We respect your privacy. We will never share your information with any third party. For full details see our privacy policy.
Breakthrough T1D is supporting a major new call to action urging Government and the sport and physical activity sector to remove barriers faced by people living with diabetes.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
We're delighted to announce a £350,000 donation from the Bukhman Foundation to support our Community Engagement programme.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
Highlights from an extraordinary year in type 1 diabetes (T1D) research, treatment, advocacy and policy.
These are the takeaways that matter most to our community from EASD, Europe’s biggest diabetes conference.
INNODIA has announced positive results from its clinical trial MELD-ATG at the EASD conference in Vienna this year.
